AR032641A1 - Agonista de subtipo de receptor 5-ht 1a. - Google Patents
Agonista de subtipo de receptor 5-ht 1a.Info
- Publication number
- AR032641A1 AR032641A1 ARP020100118A ARP020100118A AR032641A1 AR 032641 A1 AR032641 A1 AR 032641A1 AR P020100118 A ARP020100118 A AR P020100118A AR P020100118 A ARP020100118 A AR P020100118A AR 032641 A1 AR032641 A1 AR 032641A1
- Authority
- AR
- Argentina
- Prior art keywords
- subtipe
- agonist
- receiver
- carbon
- bond
- Prior art date
Links
- 239000000556 agonist Substances 0.000 title 1
- 208000012902 Nervous system disease Diseases 0.000 abstract 1
- 239000004480 active ingredient Substances 0.000 abstract 1
- 239000011203 carbon fibre reinforced carbon Substances 0.000 abstract 1
- 125000005606 carbostyryl group Chemical group 0.000 abstract 1
- 208000015114 central nervous system disease Diseases 0.000 abstract 1
- LISFMEBWQUVKPJ-UHFFFAOYSA-N quinolin-2-ol Chemical class C1=CC=C2NC(=O)C=CC2=C1 LISFMEBWQUVKPJ-UHFFFAOYSA-N 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Addiction (AREA)
- Reproductive Health (AREA)
- Endocrinology (AREA)
- Hospice & Palliative Care (AREA)
- Psychology (AREA)
- Pain & Pain Management (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Anesthesiology (AREA)
- Gynecology & Obstetrics (AREA)
- Hematology (AREA)
- Child & Adolescent Psychology (AREA)
- Otolaryngology (AREA)
- Toxicology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Quinoline Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US77021001A | 2001-01-29 | 2001-01-29 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR032641A1 true AR032641A1 (es) | 2003-11-19 |
Family
ID=25087808
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP020100118A AR032641A1 (es) | 2001-01-29 | 2002-01-15 | Agonista de subtipo de receptor 5-ht 1a. |
| ARP100104973A AR079761A2 (es) | 2001-01-29 | 2010-12-28 | Agonista de subtipo de receptor 5-ht1a |
| ARP110101189A AR080849A2 (es) | 2001-01-29 | 2011-04-08 | Uso de una composicion farmaceutica de un compuesto de carboestirilo |
| ARP150100766A AR099754A2 (es) | 2001-01-29 | 2015-03-13 | Composición farmacéutica agonista de subtipo de receptor 5-ht₁a |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP100104973A AR079761A2 (es) | 2001-01-29 | 2010-12-28 | Agonista de subtipo de receptor 5-ht1a |
| ARP110101189A AR080849A2 (es) | 2001-01-29 | 2011-04-08 | Uso de una composicion farmaceutica de un compuesto de carboestirilo |
| ARP150100766A AR099754A2 (es) | 2001-01-29 | 2015-03-13 | Composición farmacéutica agonista de subtipo de receptor 5-ht₁a |
Country Status (19)
| Country | Link |
|---|---|
| EP (3) | EP1355639B1 (enExample) |
| JP (4) | JP4178032B2 (enExample) |
| KR (5) | KR100653591B1 (enExample) |
| CN (3) | CN1239154C (enExample) |
| AR (4) | AR032641A1 (enExample) |
| AT (3) | ATE504293T1 (enExample) |
| AU (4) | AU2002226752C1 (enExample) |
| BR (1) | BR0206237A (enExample) |
| CA (2) | CA2429496C (enExample) |
| CY (3) | CY1105631T1 (enExample) |
| DE (3) | DE60220325T2 (enExample) |
| DK (3) | DK1355639T3 (enExample) |
| ES (3) | ES2363366T3 (enExample) |
| MX (2) | MX344556B (enExample) |
| MY (1) | MY129355A (enExample) |
| PH (1) | PH12014500937A1 (enExample) |
| PT (3) | PT1621198E (enExample) |
| TW (2) | TWI302832B (enExample) |
| WO (1) | WO2002060423A2 (enExample) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR032641A1 (es) * | 2001-01-29 | 2003-11-19 | Otsuka Pharma Co Ltd | Agonista de subtipo de receptor 5-ht 1a. |
| US7053092B2 (en) | 2001-01-29 | 2006-05-30 | Otsuka Pharmaceutical Co., Ltd. | 5-HT1a receptor subtype agonist |
| US8703772B2 (en) | 2001-09-25 | 2014-04-22 | Otsuka Pharmaceutical Co., Ltd. | Low hygroscopic aripiprazole drug substance and processes for the preparation thereof |
| AR033485A1 (es) | 2001-09-25 | 2003-12-26 | Otsuka Pharma Co Ltd | Sustancia medicinal de aripiprazol de baja higroscopicidad y proceso para la preparacion de la misma |
| DE10148233A1 (de) * | 2001-09-28 | 2003-04-10 | Boehringer Ingelheim Pharma | Verbindungen zur Reduzierung übermäßiger Nahrungsaufnahme |
| MXPA05000294A (es) * | 2002-07-30 | 2005-08-19 | Peter Migaly | Terapia combinada para la depresion, prevencion de suicidios y varias condiciones medicas y psiquiatricas. |
| AU2003295235B2 (en) | 2002-12-27 | 2008-06-19 | Otsuka Pharmaceutical Co., Ltd. | Carbostyril derivatives and serotonin reuptake inhibitors for treatment of mood disorders |
| AR042806A1 (es) | 2002-12-27 | 2005-07-06 | Otsuka Pharma Co Ltd | Combinacion de derivados de carboestirilo e inhibidores de la reabsorcion de serotonina para el tratamiento de trastornos del animo |
| CN102166359A (zh) * | 2003-05-23 | 2011-08-31 | 大塚制药株式会社 | 用于治疗情感障碍的喹诺酮衍生物和情绪稳定剂 |
| US7160888B2 (en) | 2003-08-22 | 2007-01-09 | Warner Lambert Company Llc | [1,8]naphthyridin-2-ones and related compounds for the treatment of schizophrenia |
| FR2865650B1 (fr) * | 2004-01-30 | 2008-06-13 | Biocortech | Utilisation du 14,15 dihydro 20,21-dinoreburnamenin14-ol pour traiter et/ou prevenir les depressions majeures et les desordres du cycle veille-sommeil |
| WO2006090273A2 (en) * | 2005-02-22 | 2006-08-31 | Warner-Lambert Company Llc | [1,8]naphthyridin-2-ones and related compounds with keto or hydroxyl linkers for the treatment of schizophrenia |
| EP1912650B8 (en) * | 2005-08-03 | 2017-10-18 | Sprout Pharmaceuticals, Inc. | Use of flibanserin in the treatment of obesity |
| TW200848041A (en) | 2007-03-30 | 2008-12-16 | Otsuka Pharma Co Ltd | A medicament for treating schizophrenia comprising cilostazol |
| GB2456183A (en) | 2008-01-04 | 2009-07-08 | Gw Pharma Ltd | Anti-psychotic composition comprising cannabinoids and anti-psychotic medicament |
| JP2009286740A (ja) * | 2008-05-30 | 2009-12-10 | Otsuka Pharmaceut Co Ltd | アリピプラゾールを含有する逆耐性抑制剤 |
| EP2338873A1 (en) | 2009-12-22 | 2011-06-29 | Gmeiner, Peter | New aminotetraline derivatives |
| TW201343201A (zh) | 2012-03-06 | 2013-11-01 | Otsuka Pharma Co Ltd | 持續釋放型口服固體製劑 |
| JOP20200109A1 (ar) | 2012-04-23 | 2017-06-16 | Otsuka Pharma Co Ltd | مستحضر قابل للحقن |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS54130587A (en) * | 1978-03-30 | 1979-10-09 | Otsuka Pharmaceut Co Ltd | Carbostyryl derivative |
| JPS5646812A (en) * | 1979-09-27 | 1981-04-28 | Otsuka Pharmaceut Co Ltd | Central nervous system depressant |
| DE3721799C2 (de) | 1986-07-01 | 1993-12-23 | Mitsubishi Electric Corp | Integrierte Redox-Bauelementschaltung und Verfahren zum Herstellen |
| US5006528A (en) * | 1988-10-31 | 1991-04-09 | Otsuka Pharmaceutical Co., Ltd. | Carbostyril derivatives |
| JP2608788B2 (ja) * | 1988-10-31 | 1997-05-14 | 大塚製薬 株式会社 | 精神分裂病治療剤 |
| EP0586525B1 (en) * | 1991-05-20 | 1997-04-16 | PHARMACIA & UPJOHN COMPANY | Carboxamido-(1,2n)-carbocyclic-2-aminotetralin derivatives |
| US5532240A (en) * | 1991-12-26 | 1996-07-02 | Yoshitomi Pharmaceutical Industries, Ltd. | Condensed thiophene compound and pharmaceutical use thereof |
| WO1994009765A1 (en) * | 1992-10-23 | 1994-05-11 | New York University | Functional interactions between glial s-100b and central nervous system serotonergic neurons |
| DK148292D0 (da) * | 1992-12-09 | 1992-12-09 | Lundbeck & Co As H | Forbindelser |
| JP2959615B2 (ja) * | 1993-06-24 | 1999-10-06 | 吉富製薬株式会社 | 縮合型チオフェン化合物およびその医薬用途 |
| JPH09291034A (ja) * | 1996-02-27 | 1997-11-11 | Yoshitomi Pharmaceut Ind Ltd | 縮合ピリジン化合物およびその医薬としての用途 |
| US5688950A (en) * | 1996-04-23 | 1997-11-18 | Neurogen Corporation | Tricyclic aminoalkylcarboxamides; novel dopamine D3 receptor subtype specific ligands |
| US6110918A (en) * | 1996-05-07 | 2000-08-29 | Pfizer Inc | Mesylate trihydrate salt of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)ethyl)-6-chloro-1,3-dihy dro-2(1H)-indol-2-one (=ziprasidone), its preparation and its use as dopamine D2 antagonist |
| JP4012994B2 (ja) * | 1996-05-08 | 2007-11-28 | 大塚製薬株式会社 | 抗不安薬 |
| AU4091697A (en) * | 1996-08-27 | 1998-03-19 | American Home Products Corporation | 4-aminoethoxy indoles as dopamin d2 agonists and as 5ht1a ligands |
| EP1053235A1 (en) * | 1998-02-03 | 2000-11-22 | American Home Products Corporation | Oxazole derivatives as serotonin-1a receptor agonists |
| WO1999052870A1 (en) * | 1998-04-13 | 1999-10-21 | American Home Products Corporation | 4-amino-(ethylamino)-oxindole dopamine autoreceptor agonists |
| JPH11335286A (ja) * | 1998-05-25 | 1999-12-07 | Mitsui Chem Inc | ドーパミン拮抗薬の効果増強剤 |
| AR032641A1 (es) * | 2001-01-29 | 2003-11-19 | Otsuka Pharma Co Ltd | Agonista de subtipo de receptor 5-ht 1a. |
| DE60234873D1 (de) * | 2001-06-19 | 2010-02-04 | Norbert Mueller | Verwendung von COX-2 Inhibitoren zur Behandlung von affectiven Störungen |
| AR033485A1 (es) * | 2001-09-25 | 2003-12-26 | Otsuka Pharma Co Ltd | Sustancia medicinal de aripiprazol de baja higroscopicidad y proceso para la preparacion de la misma |
-
2002
- 2002-01-15 AR ARP020100118A patent/AR032641A1/es not_active Application Discontinuation
- 2002-01-25 TW TW091101289A patent/TWI302832B/zh not_active IP Right Cessation
- 2002-01-25 TW TW093127321A patent/TWI331919B/zh not_active IP Right Cessation
- 2002-01-26 MY MYPI20020297A patent/MY129355A/en unknown
- 2002-01-29 ES ES06015782T patent/ES2363366T3/es not_active Expired - Lifetime
- 2002-01-29 AT AT06015782T patent/ATE504293T1/de active
- 2002-01-29 CA CA2429496A patent/CA2429496C/en not_active Expired - Lifetime
- 2002-01-29 JP JP2002560616A patent/JP4178032B2/ja not_active Expired - Lifetime
- 2002-01-29 MX MX2011010975A patent/MX344556B/es unknown
- 2002-01-29 DE DE60220325T patent/DE60220325T2/de not_active Expired - Lifetime
- 2002-01-29 CN CNB028035518A patent/CN1239154C/zh not_active Expired - Lifetime
- 2002-01-29 EP EP02716434A patent/EP1355639B1/en not_active Expired - Lifetime
- 2002-01-29 ES ES02716434T patent/ES2261652T3/es not_active Expired - Lifetime
- 2002-01-29 AT AT02716434T patent/ATE322894T1/de active
- 2002-01-29 KR KR1020057019896A patent/KR100653591B1/ko not_active Expired - Lifetime
- 2002-01-29 PT PT05023971T patent/PT1621198E/pt unknown
- 2002-01-29 KR KR1020067005164A patent/KR100763288B1/ko not_active Ceased
- 2002-01-29 KR KR1020037008565A patent/KR100601073B1/ko not_active Expired - Lifetime
- 2002-01-29 AT AT05023971T patent/ATE362763T1/de active
- 2002-01-29 CN CNB2005100228288A patent/CN100450485C/zh not_active Expired - Lifetime
- 2002-01-29 EP EP06015782A patent/EP1712225B1/en not_active Revoked
- 2002-01-29 CN CNA2006100943881A patent/CN1879624A/zh active Pending
- 2002-01-29 MX MXPA03006603A patent/MXPA03006603A/es active IP Right Grant
- 2002-01-29 ES ES05023971T patent/ES2286755T3/es not_active Expired - Lifetime
- 2002-01-29 AU AU2002226752A patent/AU2002226752C1/en not_active Expired
- 2002-01-29 KR KR1020077010561A patent/KR100825705B1/ko not_active Expired - Lifetime
- 2002-01-29 DK DK02716434T patent/DK1355639T3/da active
- 2002-01-29 DE DE60210581T patent/DE60210581T2/de not_active Expired - Lifetime
- 2002-01-29 PT PT06015782T patent/PT1712225E/pt unknown
- 2002-01-29 CA CA2700314A patent/CA2700314C/en not_active Expired - Lifetime
- 2002-01-29 BR BR0206237-2A patent/BR0206237A/pt not_active Application Discontinuation
- 2002-01-29 DE DE60239711T patent/DE60239711D1/de not_active Expired - Lifetime
- 2002-01-29 DK DK05023971T patent/DK1621198T3/da active
- 2002-01-29 PT PT02716434T patent/PT1355639E/pt unknown
- 2002-01-29 KR KR1020067014046A patent/KR100713607B1/ko not_active Expired - Lifetime
- 2002-01-29 WO PCT/JP2002/000626 patent/WO2002060423A2/en not_active Ceased
- 2002-01-29 EP EP05023971A patent/EP1621198B1/en not_active Revoked
- 2002-01-29 DK DK06015782.3T patent/DK1712225T3/da active
-
2005
- 2005-04-27 AU AU2005201772A patent/AU2005201772C1/en not_active Expired
-
2006
- 2006-06-28 CY CY20061100884T patent/CY1105631T1/el unknown
-
2007
- 2007-04-17 AU AU2007201701A patent/AU2007201701B2/en not_active Expired
- 2007-07-09 JP JP2007179275A patent/JP4896831B2/ja not_active Expired - Lifetime
- 2007-08-20 CY CY20071101093T patent/CY1108031T1/el unknown
-
2009
- 2009-10-29 AU AU2009233591A patent/AU2009233591B2/en not_active Expired
-
2010
- 2010-12-28 AR ARP100104973A patent/AR079761A2/es not_active Application Discontinuation
-
2011
- 2011-04-08 AR ARP110101189A patent/AR080849A2/es not_active Application Discontinuation
- 2011-04-18 CY CY20111100391T patent/CY1111392T1/el unknown
- 2011-06-15 JP JP2011133032A patent/JP5683010B2/ja not_active Expired - Lifetime
- 2011-06-15 JP JP2011133033A patent/JP2011184460A/ja active Pending
-
2014
- 2014-04-28 PH PH12014500937A patent/PH12014500937A1/en unknown
-
2015
- 2015-03-13 AR ARP150100766A patent/AR099754A2/es not_active Application Discontinuation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR032641A1 (es) | Agonista de subtipo de receptor 5-ht 1a. | |
| ATE459357T1 (de) | Kombinationen zur behandlung von multiplem myelom | |
| GT200000019A (es) | Inhibidores de la recaptacion de monoaminas para el tratamiento de trastornos del snc. | |
| EP2178870A4 (en) | INDOL AND INDAZONE COMPOUNDS AS AN INHIBITORS OF CELL NECROSIS | |
| WO2005013892A3 (en) | Hydrolytically-resistant boron-containing therapeutics and methods of use | |
| ATE466014T1 (de) | Spiroazacyclische verbindungen als monoaminrezeptormodulatoren | |
| ATE482209T1 (de) | Verbindungen und zusammensetzungen als modulatoren der gpr119-aktivität | |
| MA31158B1 (fr) | Composes tricycliques et leur utilisation comme modulateurs du recepteur de glucocorticoïdes | |
| PT1543011E (pt) | Composto de tienopirrolilo e furanopirrolilo e sua utilizacao como ligandos do receptor h4 da histamina | |
| NO20082011L (no) | Acylerte spiropiperidinderivater som melanocortin-4-reseptormodulatorer | |
| UY33020A (es) | INHIBIDORES DE N1-PIRAZOLOESPIROCETONA ACETIL-CoA CARBOXILASA | |
| MXPA05002942A (es) | Forma de dosificacion oral de liberacion modificada. | |
| CY1107747T1 (el) | Υποκατεστημενα τετρακυκλικα παραγωγα πυρρολοκινολονης χρησιμα ως αναστολεις της φωσφοδιεστερασης | |
| UA103930C2 (ru) | Соединения и композиция для лечения паразитарных болезней | |
| MX2010003948A (es) | N-fenil-birrolidin ureas sustituidas y uso terapeutico de las mismas. | |
| EA200700909A1 (ru) | Азаиндолкарбоксамиды | |
| TW200736229A (en) | Substituted 1H-benzimidazole-4-carboxamides are potent PARP inhibitors | |
| MY124786A (en) | Bis-arylsulfones | |
| NO20054494L (no) | Peptidvektorer | |
| GT200400041A (es) | Derivados azabiciclicos de piridiloximetilo y bencisoxazol | |
| WO2001091796A8 (en) | Methods, compounds and compositions for treating gout | |
| GT199700096A (es) | Ligandos espirociclos de un subtipo de receptor de la dopamina. | |
| UA106200C2 (uk) | Заміщені похідні оксіндолу та їхнє застосування для лікування захворювань, залежних від вазопресину | |
| UA74430C2 (uk) | Похідні фенілгетероциклічних етерів як інгібітори зворотного захоплення серотоніну | |
| PA8567701A1 (es) | Agonistas del receptor b3-adrenergico |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Refusal |